Wang Kaihao, Wang Wenyao, Zhang Kuo, Gao Jun, Liu Yupeng, Zheng Jilin, Li Ping, Tang Yida
Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ann Transl Med. 2021 Feb;9(4):294. doi: 10.21037/atm-20-5541.
Altered thyroid function and increased N-terminal pro-B-type natriuretic peptide (NT-proBNP) are prognostic factors in acute myocardial infarction (AMI). The study aims to investigate whether free triiodothyronine (fT3) and NT-proBNP are prognostic factors for long-term outcomes in patients with AMI undergoing percutaneous coronary intervention (PCI).
This was an observational, prospective, single-center study of consecutive patients enrolled at Fuwai Hospital between January, 2013 and December, 2013. The patients were divided into two groups according to fT3 levels: low fT3 (<2.5 pg/mL) and normal fT3 (2.50-4.09 pg/mL). The primary outcome of this study was the incidence of major adverse cardiovascular events (MACEs).
There were 252 patients with low fT3 and 561 patients with normal fT3. After >2 years of follow-up, patients with low fT3 levels had higher rates of MACEs than those with normal fT3 (27.0% 7.8%, P<0.001). Univariable Cox proportional hazards regression analyses showed that NT-proBNP >802.7 pg/mL [hazard ratio (HR) =5.063, 95% confidence interval (CI): 3.176-8.071, P<0.001] and fT3 <2.5 pg/mL (HR =3.867, 95% CI: 2.646-5.651, P<0.001) were the strongest predictors of MACEs. After adjustment for traditional risk predictors, fT3 <2.5 pg/mL (HR =2.570, 95% CI: 1.653-3.993, P<0.001) was one of the most important independent predictors of MACEs. Patients with NT-proBNP ≤802.7 pg/mL and fT3 ≥2.5 pg/mL had the best prognosis, while patients with NT-proBNP >802.7 pg/mL and fT3 <2.5 pg/mL had the worst outcomes (P<0.001).
Low fT3 is a strong predictor of poor prognosis after AMI. The fT3+NT-proBNP combination might be a valuable predictor of the long-term outcomes of PCI after AMI.
甲状腺功能改变及N末端B型利钠肽原(NT-proBNP)升高是急性心肌梗死(AMI)的预后因素。本研究旨在探讨游离三碘甲状腺原氨酸(fT3)和NT-proBNP是否为接受经皮冠状动脉介入治疗(PCI)的AMI患者长期预后的预后因素。
这是一项对2013年1月至2013年12月在阜外医院连续入选患者进行的观察性、前瞻性、单中心研究。根据fT3水平将患者分为两组:低fT3(<2.5 pg/mL)和正常fT3(2.50 - 4.09 pg/mL)。本研究的主要结局是主要不良心血管事件(MACE)的发生率。
有252例低fT3患者和561例正常fT3患者。经过>2年的随访,低fT3水平患者的MACE发生率高于正常fT3患者(27.0%对7.8%,P<0.001)。单变量Cox比例风险回归分析显示,NT-proBNP>802.7 pg/mL[风险比(HR)=5.063,95%置信区间(CI):3.176 - 8.071,P<0.001]和fT3<2.5 pg/mL(HR =3.867,95%CI:2.646 - 5.651,P<0.001)是MACE最强的预测因素。在对传统风险预测因素进行校正后,fT3<2.5 pg/mL(HR =2.570,95%CI:1.653 - 3.993,P<0.001)是MACE最重要的独立预测因素之一。NT-proBNP≤802.7 pg/mL且fT3≥2.5 pg/mL的患者预后最佳,而NT-proBNP>802.7 pg/mL且fT3<2.5 pg/mL的患者结局最差(P<0.001)。
低fT3是AMI后预后不良的有力预测因素。fT3 + NT-proBNP联合检测可能是AMI后PCI长期结局的有价值预测指标。